Drug · CHEMBL1200796
CYCLOPHOSPHAMIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CYCLOPHOSPHAMIDE. Drugs and targets, record CHEMBL1200796. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1200796
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
B-518, Ciclofosfamide, Cycloblastin, Cyclophosphamide hydrate, Cyclophosphamide monohydrate, Cyclophosphamidum, Cyclophosphanum, Cyclostin, Cytophosphan, Cytophosphane, Endoxan, Endoxan monohydrate, NSC-26271, NSC-756711, Procytox, Revimmune
- ChEMBL
- Open Targets' highest stage
- Approval, for 7 of its 423 diseases, from ATC, ClinicalTrials.gov and DailyMed
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases423
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| breast cancer | Phase 3 | ClinicalTrials.gov | 531 | 531 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 249 | 249 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| diffuse large B-cell lymphoma | Phase 3 | ClinicalTrials.gov | 239 | 239 | https://conductscience.org/library/drugs?q=MONDO_0018905 |
| plasma cell myeloma | Approval | DailyMed | 239 | 235 | https://conductscience.org/library/drugs?q=MONDO_0009693 |
| non-Hodgkin lymphoma | Phase 3 | ClinicalTrials.gov | 205 | 205 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
| acute myeloid leukemia | Phase 3 | ClinicalTrials.gov | 145 | 145 | https://conductscience.org/library/drugs?q=MONDO_0018874 |
| B-cell chronic lymphocytic leukemia | Phase 3 | ClinicalTrials.gov | 138 | 138 | https://conductscience.org/library/drugs?q=MONDO_0004948 |
| hematopoietic and lymphoid cell neoplasm | Phase 3 | ClinicalTrials.gov | 133 | 133 | https://conductscience.org/library/drugs?q=MONDO_0044881 |
| myelodysplastic syndrome | Phase 3 | ClinicalTrials.gov | 104 | 104 | https://conductscience.org/library/drugs?q=MONDO_0018881 |
| Hodgkins lymphoma | Approval | DailyMed | 94 | 93 | https://conductscience.org/library/drugs?q=MONDO_0004952 |
1 to 10 of 423Source Open Targets
See all 423 diseasesTrials3,516
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 18 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01190930 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | Phase 3 | 9,350 | 2020-06-23 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT02883049 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | Phase 3 | 5,949 | 2024-03-12 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT00103285 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Phase 3 | 5,377 | 2018-07-11 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT00003782 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | Phase 3 | 5,351 | 2012-10-31 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | Phase 3 | 4,994 | 2019-09-04 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT00093795 | Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | Phase 3 | 4,894 | 2017-12-12 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | Phase 3 | 4,804 | 2018-01-05 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT00041119 | Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer | Phase 3 | 3,871 | 2017-05-18 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT00312208 | Docetaxel in Breast Cancer | Phase 3 | 3,299 | 2010-02-17 | cyclophosphamide | Its name | ClinicalTrials.gov |
| NCT00070564 | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | Phase 3 | 3,294 | 2017-04-17 | cyclophosphamide | Its name | ClinicalTrials.gov |
1 to 10 of 3,516
See all 3,516 trialsComparisons in its trials686
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29) | 4,378 of 4,609 | 258 of 362 | 4,971 | NCT00103285 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 | 247 of 2,404 | 4,804 | NCT01358877 | Trial comparisons |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: serious adverse events | 792 of 2,364 | 686 of 2,405 | 4,769 | NCT01358877 | Trial comparisons |
Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival) | 356 of 1,649 | 352 of 1,649 | 3,298 | NCT00312208 | Trial comparisons |
| Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): Death From Any Cause (Overall Survival) | 187 of 1,649 | 202 of 1,649 | 3,298 | NCT00312208 | Trial comparisons |
| Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T) vs Docetaxel + Doxorubicin and Cyclophosphamide (TAC): serious adverse events | 331 of 1,634 | 520 of 1,635 | 3,269 | NCT00312208 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause | 48 of 1,622 | 61 of 1,628 | 3,250 | NCT01275677 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events | 31 of 1,615 | 96 of 1,625 | 3,240 | NCT01275677 | Trial comparisons |
| Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events | 12 of 1,351 | 26 of 1,337 | 2,688 | NCT00087178 | Trial comparisons |
| Chemotherapy vs Atezolizumab and Chemotherapy: deaths from any cause | 58 of 1,098 | 72 of 1,101 | 2,199 | NCT03498716 | Trial comparisons |
1 to 10 of 686
See all 686 comparisons in its trialsPapers from its trials2,248
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials19
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 3 | 0 | ConductCognition |
| Block Copy Test | 2 | 0 | ConductCognition |
| Stroop Color-Word Test | 2 | 0 | ConductCognition |
| Symbol Coding | 2 | 0 | ConductCognition |
| Symbol Scan Task | 2 | 0 | ConductCognition |
| Verbal Fluency | 2 | 0 | ConductCognition |
| Arithmetic Fluency Task | 1 | 0 | ConductCognition |
| Category Fluency | 1 | 0 | ConductCognition |
| Clock Drawing Task | 1 | 0 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
1 to 10 of 19
See all 19 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1200796
GET https://conductscience.org/api/drugs/v1/CHEMBL1200796/diseases?page=2